The Enterprise Value as of November 2024 (TTM) for Replimune Group, Inc. (REPL) is 984.10M

According to Replimune Group, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 984.10M. This represents a change of 63.22% compared to the average of 602.94M of the last 4 quarters.

Replimune Group, Inc. (REPL) Historical Enterprise Value (quarterly & annually)

How has REPL Enterprise Value performed in the past?

The mean historical Enterprise Value of Replimune Group, Inc. over the last ten years is 619.15M. The current 984.10M Enterprise Value has changed 15.79% with respect to the historical average. Over the past ten years (40 quarters), REPL's Enterprise Value was at its highest in in the June 2021 quarter at 1.83B. The Enterprise Value was at its lowest in in the September 2017 quarter at 0.

Replimune Group, Inc. (REPL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Replimune Group, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Replimune Group, Inc. (REPL) Average Enterprise Value

How has REPL Enterprise Value performed in the past?

The current Enterprise Value of Replimune Group, Inc. (REPL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Replimune Group, Inc. (REPL) Enterprise Value vs. Peers

How is REPL’s Enterprise Value compared to its peers?

Replimune Group, Inc.’s Enterprise Value is less than Nuvalent, Inc. (6.38B), greater than Ventyx Biosciences, Inc. (80.09M), less than Ascendis Pharma A/S (7.61B), less than United Therapeutics Corporation (15.49B), greater than Nuvectis Pharma, Inc. (81.37M), greater than Lyra Therapeutics, Inc. (23.90M), greater than Kronos Bio, Inc. (5.32M), greater than Gossamer Bio, Inc. (331.04M), greater than Kura Oncology, Inc. (807.00M), less than Protagonist Therapeutics, Inc. (2.65B), less than Merus N.V. (2.68B), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Aerovate Therapeutics, Inc. (46.23M), less than Keros Therapeutics, Inc. (1.75B), less than Syndax Pharmaceuticals, Inc. (1.24B), greater than Mineralys Therapeutics, Inc. (523.81M), less than Crinetics Pharmaceuticals, Inc. (4.93B), less than NewAmsterdam Pharma Company N.V. (1.37B), greater than PureTech Health plc (376.11M),

Build a custom stock screener for Replimune Group, Inc. (REPL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Replimune Group, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Replimune Group, Inc. (REPL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Replimune Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.